Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

20173,357 citationsJournal Articlebronze Open Access

Authors

Joaquim Bellmunt · Dana-Farber Cancer Institute

Ronald de Wit · Erasmus MC Cancer Institute

David J. Vaughn · University of Pennsylvania

Yves Fradet · Radboud University Medical Center

Jae‐Lyun Lee · Radboud University Nijmegen

Lawrence Fong · Erasmus MC Cancer Institute

Nicholas J. Vogelzang

Abstract

Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).

Topics & Keywords

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary and Genital Oncology Studies

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 11, pp. 1015-1026

DOI: 10.1056/nejmoa1613683

Field-Weighted Citation Impact: 348.66

Command Palette

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Authors

Abstract

Topics & Keywords

Publication Details